Premenstrual exacerbation of symptoms in multiple sclerosis is attenuated by treatment with weak electromagnetic fields

International Journal of Neuroscience

Volumn 83, Issue 3-4, 1995, Pages 187-198

  Sandyk, Reuven ^a,b  

^a NeuroCommunication Res Laboratories   (United States)

^b TOURO COLLEGE   (United States)

Author keywords

Electromagnetic fields; Endorphins; Immune responses; Melatonin; Menstrual cycle; Multiple sclerosis; Pineal gland; Premenstrual syndrome

Indexed keywords

ADULT; ARTICLE; CASE REPORT; ELECTROMAGNETIC FIELD; ELECTROSTIMULATION THERAPY; FEMALE; HUMAN; MIDDLE AGED; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PREMENSTRUAL SYNDROME;

ADULT; ELECTRIC STIMULATION THERAPY; ELECTROMAGNETIC FIELDS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PREMENSTRUAL SYNDROME;

EID: 0029585449     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459508986338     Document Type: Article

References (139)

1. Treatment of pain multiple sclerosis
2. Effects of pinealectomy on regional brain serotonin metabolism
3. Biochemical effects of steroid contraceptive drugs on some neurotransmitters in the central nervous system
4. Effect of exogenous melatonin on-human natural killer (NK) cell activity: an approach to the immunomodulatory role of the pineal gland
5. Brain serotonin concentration elevation following intraperitoneal administration of melatonin
6. Melatonin assays in body fluids
7. Pregnancy and multiple sclerosis
8. The clinical course of multiple sclerosis during pregnancy and the puerperium
9. Pregnancy and multiple sclerosis. Case report
10. Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptive
11. The role of a thymus-pineal axis in an immune mechanism of aging
12. Negative effects of melatonin on depression
13. Hormones, behavior and the menstrual cycle
14. Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis
15. Pain in multiple sclerosis
16. Clinical and experimental studies of stress and the opioid system
17. Menstruation and personality
18. Monoamine metabolites in cerebrospinal fluid in multiple sclerosis
19. Multiple sclerosis in pregnancy: a review
20. Factors associated with a rapid course of multiple sclerosis
21. Hormonal factors in susceptibility to multiple sclerosis
22. The increased susceptibility of women to multiple sclerosis
23. Endogenous opioid peptides and the menstrual cycle
24. Multiple sclerosis: a two stage process
25. Inflammatory demyelinating diseases of the CNS
26. Endocrinological effects of strong 60-Hz electric fields on rats
27. Comparison of seasonal and nonseasonal affective disorder
28. Pregnancy: a factor influencing the course of multiple sclerosis
29. Severely threatening events and marked life difficulties preceding onset and exacerbation of MS
30. A brief survey of pineal gland-immune system interrelationships
31. Estrogen receptors in macrophages
32. Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity
33. Corticosterone levels in mice exposed to high intensity electric fields
34. Relationship of dysphoric premenstrual changes to depressive disorders
35. Premenstrual changes. Impaired hormonal homeostasis
36. The premenstrual syndrome: an equivalent of depression
37. Circadian rhythm of plasma melatonin and cortisol during the menstrual cycle
38. Effects of L-tryptophan on central indoleamire metabolism and short-lasting neurologic disturbances in multiple sclerosis
39. Premenstrual tension
40. Effect of pinealectomy on immune reactions in the rat
41. Tolerance to morphine-induced analgesia in mice: magnetic fields function as environmental specific cues and reduce tolerance development
42. Stress-induced opioid analgesia and activity in mice: inhibitory influences of exposure to magnetic fields
43. Magnetic fields differentially inhibit mu, delta, kappa and sigma opiate-induced analgesia in mice
44. Magnetic field inhibition of morphine-induced analgesia and behavioral activity in mice: evidence for involvement of calcium ions
45. Magnetic fields, opioid systems, and day-night rhythms of behavior
46. Magnetic fields abolish the enhanced nocturnal analgesic response to morphine in mice
47. Amino acid determinations in serum of patients with multiple sclerosis
48. Activity of multiple sclerosis during pregnancy and puerperium
49. The regulation of the menstrual cycle and its relationship co the moon
50. Immunopharmacological disease: a break in tolerance to receptor sites
51. Light suppresses melatonin secretion in humans
52. A clinical study on the relationship between the pineal gland and the opioid system
53. Determination of serotonin content and ceruloplasmin activity of blood and CSF amino acid level in multiple sclerosis
54. The pineal gland and the circadian, opiatergic, immunoregulatory role of melatonin
55. Melatonin counteracts the effect of acute stress on the immune system via an opiatergic system
56. Role of the pineal gland in immunity. III: Melatonin antagonizes the immunosuppressive effect of acute stress via an opiatergic mechanism
57. Effects of the menstrual cycle on medical disorders
58. Altered serotonin uptake kinetics in multiple sclerosis
59. The frequency of multiple sclerosis in Western Australia
60. Factors in postmeridial hormone changes among rats in electric field exposure studies
61. Pregnancy as a factor influencing relapse in disseminated sclerosis
62. Biochemical fractions and mechanisms involved in the pineal modulation of pituitary gonadotropin release
63. Treatment of a patient with season premenstrual syndrome
64. Morning versus evening bright light treatment of late luteal phase dysphoric disorder
65. Altered wave form of plasma noturnal melatonin secretion in premenstrual depression
66. Melatonin excretion in normal males and females: increase during pregnancy
67. Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects
68. Neuroimmunomodulation: some recent views and findings
69. Fluoxetine treatment of premenstrual syndrome
70. Multiple sclerosis and gestation
71. The pharmacology of myoclonus
72. Menstrual-related fluctuations in Parkinson's disease
73. Endogenous opioid activity and the premenstrual syndrome
74. Premenstrual syndrome
75. The premenstrual syndrome
76. Pineal gland. Interface between the photoperiodic environment and the endocrine system
77. Immunocompetence of pinealectomized and simulateneously pinealectomized and thymectornized rats
78. Fluoxetine in the treatment of premenstrual syndrome
79. Amantadine, fatigue, and multiple sclerosis
80. Antidepressant effects of light in seasonal affective disorder
81. Neuroanatomic and neurotransmitter influences on immune function
82. Menstrually-related mood disorders
83. Static magnetic fields decrease nocturnal pineal cAMP in the rat
84. Treatment of stable chronic demyelinating polyneuropathy with 3, 4-diaminopyridine
85. The Pineal gland and the menstrual cycle
86. Successful treatment of multiple sclerosis with magnetic fields
87. The pineal gland and multiple sclerosis, (Editorial)
88. Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis
89. Further observations on the effects of external picotesla range magnetic fields on visual memory and visuospatial functions in multiple sclerosis
90. Rapid normalization of visual evoked potentials by picotesla range magnetic fields in chronic progressive multiple sclerosis
91. The pineal gland in multiple sclerosis
92. Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis
93. Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders
94. Nocturnal melatonin secretion in suicidal patients with multiple sclerosis
95. Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis
96. The co-occurrence of multiple sclerosis and migraine headaches: the serotonergic link
97. Successful treatment of an acute exacerbation of multiple sclerosis by external magnetic fields
98. Magnetic fields normalize visual evoked potentials and brainstem auditory evoked potentials in multiple sclerosis
99. Resolution of longstanding symptoms of multiple sclerosis by application of picotesla range magnetic fields
100. Multiple sclerosis: Improvement of visuoperceptive functions by picotesla range magnetic fields
101. Improvement by picotesia range magnetic fields of perceptual-motor performance and visual memory in a patient with chronic progressive multiple sclerosis
102. Menstrual-related fluctuations in Tourette's syndrome
103. Marriage, pregnancy and multiple sclerosis
104. Neurology of sex steroids and oral contraceptives
105. Premenstrual symptoms and depression in a university population
106. Effects of gender and sex steroids on the immune response
107. Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons
108. Effects of an earth-strength magnetic field on electrical activity of pineal cells
109. The effects of sex hormones, prolactin, and chorionic gonadotropin on pineal electrical activity in guinea pigs
110. Painful tonic seizures in multiple sclerosis
111. Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis
112. Fluoxetine in the treatment of late luteal phase dysphoric disorder
113. Secretion of growth hormone, prolactin and corticosteroids during different levels of geomagnetic activity
114. Steroid hormone target cells in the periventricular brain: relationship to peptide hormone producing cells
115. Pregnancy and multiple sclerosis
116. Ventricular fluid homovanillic acid and 5-hydroxyin-doleacetic acid concentrations in patients with movement disorders
117. Clinical aspects
118. The effect of pregnancy on multiple sclerosis and its management
119. 4-aminopyridine induces functional improvement in multiple sclerosis patients: a neuropsychiological study
120. Does the multiple-sclerosis syndrome begin at puberty
121. Some anatomical and physiological interactions among noradrenergic systems and opioid peptides
122. Emotional stress and the development of MS: case-control evidence of a relationship
123. Opiatergic modulation of the immune system
124. The circadian pattern of melatonin and its positive relationship with progesterone in women
125. Seasonality and affective illness
126. Beta-endorphin in hypophyseal portal blood variations throughout the menstrual cycle
127. Effects of an artifical magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland
128. Human serum melatonin changes during the menstrual cycle
129. Effects of electromagnetic field exposure on neuroendocrine function
130. Enkephalin opens potassium channels on mammalian central neurones
131. The human menstrual cycle